Therapeutic Approach

Archive: 2018

Ritter Pharmaceuticals Reaches Halfway Mark for Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

Full Enrollment on Target for Q2 2019 with Data Readout Expected in the Second Half of 2019 LOS ANGELES (December 4, 2018) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Progress

LOS ANGELES, Nov. 09, 2018 (GLOBE NEWSWIRE) — Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for […]

Leave Your Comments »

Ritter Pharmaceuticals Announces Closing of $6.0 Million At-Market Private Placement of Series B Convertible Preferred

Proceeds Expected to be Sufficient to Fund Company’s Liberatus Phase 3 Clinical Trial for RP-G28 for Lactose Intolerance Through Announcement of Top-Line Data Anticipated in the Second Half of 2019 LOS ANGELES (November 6, 2018) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the […]

Leave Your Comments »

Ritter Pharmaceuticals Announces Agreement for $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants

LOS ANGELES, Oct. 31, 2018 (GLOBE NEWSWIRE) — Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases (GI) with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for […]

Leave Your Comments »

Ritter Pharmaceuticals Presents Additional Phase 2b Data Showing Adaptation of the Gut Microbiome in Lactose Intolerance Patients at American College of Gastroenterology Scientific Meeting

LOS ANGELES (October 9, 2018) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance […]

Leave Your Comments »

Ritter Pharmaceuticals to Present at 20th Annual HC Wainwright Global Investment Conference on September 5, 2018

LOS ANGELES, Aug 28, 2018 (GLOBE NEWSWIRE) — Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Progress

LOS ANGELES (August 14, 2018) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance, […]

Leave Your Comments »

Ritter Pharmaceuticals Initiates First Pivotal Phase 3 Trial for RP-G28 for the Treatment of Lactose Intolerance

Conference Call Today – June 27, 2018 at 4:30 p.m. ET LOS ANGELES (June 27, 2018) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with […]

Leave Your Comments »

Ritter Pharmaceuticals Announces Appointment of Andrew J. Ritter as Chief Executive Officer

LOS ANGELES (June 27, 2018) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance […]

Leave Your Comments »

Ritter Pharmaceuticals Highlights Key Phase 2b Clinical Trial Data of RP-G28 for Lactose Intolerance at Digestive Disease Week 2018

Additional Data Describes Novel Clinical Symptom Assessment Tool Developed in Phase 2b Trial and to be Used in Upcoming Phase 3 Clinical Trial LOS ANGELES (June 5, 2018) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD